Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma

Soo Chin Lee, Seng Gee Lim, Ross Soo, Wen Son Hsieh, Jia Yi Guo, Thomas Putti, Qian Tao, Richie Soong, Boon Cher Goh

Research output: Contribution to journalArticlepeer-review

Abstract

Activating EGFR somatic mutations have been shown to predict treatment response to small molecules targeting the EGFR intracellular tyrosine kinase domain. Recent work on cell-lines and animal models had demonstrated an inhibitory effect of EGFR tyrosine kinase inhibitors in hepatocellular and nasopharyngeal carcinoma, and clinical trials in these tumour types are ongoing. There are few data on the presence or prevalence of EGFR mutations in hepatocellular and nasopharyngeal carcinomas. We studied exons 18-21 of the EGFR gene from 100 hepatocellular and 102 nasopharyngeal carcinomas, and found no exonic mutations of potential significance. Alternative mechanisms may be important for the observed activity of small molecule EGFR tyrosine kinase inhibitors in hepatocellular and nasopharyngeal carcinomas.

Original languageEnglish (US)
Pages (from-to)73-74
Number of pages2
JournalPharmacogenetics and Genomics
Volume16
Issue number1
DOIs
StatePublished - Jan 2006

Keywords

  • EGFR
  • EGFR mutations
  • EGFR tyrosine kinase inhibitors
  • Hepatocellular carcinoma
  • Nasopharyngeal carcinoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma'. Together they form a unique fingerprint.

Cite this